Search

Your search keyword '"Shepherd, F.A."' showing total 104 results

Search Constraints

Start Over You searched for: Author "Shepherd, F.A." Remove constraint Author: "Shepherd, F.A." Publisher elsevier bv Remove constraint Publisher: elsevier bv
104 results on '"Shepherd, F.A."'

Search Results

1. MA16.11 Consolidation EGFR-Tyrosine Kinase Inhibitor (TKI)vs. Durvalumab vs. Observation in Unresectable EGFR-Mutant Stage III NSCLC

2. OA01.09 Adjuvant Osimertinib in Resected EGFR-Mutated Stage IB–IIIA Non-Small Cell Lung Cancer: Updated ADAURA Results

3. 296P Osimertinib as adjuvant therapy in patients (pts) with resected EGFR-mutated (EGFRm) stage IB-IIIA non-small cell lung cancer (NSCLC): Updated results from ADAURA

4. EP08.02-082 Treatment Patterns and Outcomes of First-line Osimertinib-treated Advanced EGFR Mutated NSCLC Patients: A Real-world Study

6. 1144P Clinical outcomes of NSCLC patients (pts) who had brain-only metastasis at time of stage IV diagnosis, by presence versus absence of EGFR/ALK mutations

7. EP02.04-009 Real World Survival Outcome Analysis of Adjuvant Therapies in Non-EGFR, Non-ALK Early Stage Resected NSCLC

8. EP04.01-001 Prevalence And Outcomes of EGFR Exon 20 Insertion Mutation In NSCLC: Princess Margaret Cancer Center Experience

9. 1191TiP Nivolumab-ipilimumab with cfDNA-guided treatment intensification as a chemotherapy-sparing strategy in metastatic non-small cell lung cancer (ATLAS)

11. 1202TiP Evolution of the tumor immune microenvironment in hepatocellular carcinoma (HCC) and non-squamous non-small cell lung cancer (NSCLC) with liver metastases treated with atezolizumab and bevacizumab (INTEGRATE)

13. LBA47 Osimertinib as adjuvant therapy in patients (pts) with resected EGFR-mutated (EGFRm) stage IB-IIIA non-small cell lung cancer (NSCLC): Updated results from ADAURA

14. 181P Poor response to PD-1 inhibitors in metastatic non-small cell lung cancer (mNSCLC) patients with liver metastases may be mediated by myeloid populations

15. OA16.02 The Economic Value of Liquid Biopsy for Genomic Profiling in Advanced Non-Small Cell Lung Cancer

16. FP12.07 Clinico-demographic Factors, EGFR status and their association with Stage at Diagnosis in Lung Adenocarcinoma Patients

17. FP16.03 Early Circulating-Tumor DNA EGFR Mutation Clearance in Plasma as a Predictor of Clinical Outcomes in The AURA3 Trial

18. P45.05 Sequencing of PD-1 Inhibitors and TKIs in Metastatic NSCLC with MET Exon 14 Skipping Mutation May Influence Survival

19. OA08.04 Validation of Scalable, Automated Data Extraction in an Advanced Lung Cancer Patient Population

20. P59.17 EGFR Mutation Status, Liver Metastasis, and Overall Survival in Advanced Lung Adenocarcinoma Patients

21. P45.09 Real-World Sequencing of ALK-TKIs in Advanced Stage ALK-positive NSCLC patients in Canada

22. FP12.01 PD-L1 Assessment in Cytology is Comparable to Histology in Predicting Treatment Response to Checkpoint Inhibitors in NSCLC

23. P48.05 Is Relapse-Free Survival at 2-Years an Appropriate Surrogate for Overall Survival at 5-Years in EGFR-mutated Resected NSCLC?

25. P45.07 Real-World Clinically-Relevant Toxicities of ALK TKIs in a Cohort of Patients With Advanced/Metastatic ALK+ NSCLC

26. MA08.02 Outcomes of Early Stage ALK-positive NSCLC patients in a Real-World Cohort

27. 531P Binimetinib and encorafenib for the treatment of advanced solid tumors with non-V600E BRAF mutations (mts): Preliminary results of the investigator initiated phase II BEAVER trial

29. 1356P Cumulative incidence and baseline imaging patterns of brain metastases in advanced EGFR and ALK positive non-small cell lung cancer (NSCLC)

30. 1809P Evaluation of KRAS mutation subtype on survival in patients with metastatic non-small cell lung cancer receiving immunotherapy

31. 1298P PD-1 inhibitors combined with chemotherapy may preferentially improve survival in metastatic NSCLC with myeloid-mediated primary resistance to immunotherapy

32. 1243P Cumulative incidence and metastatic patterns of relapsed vs de novo stage IV non-small cell lung cancer (NSCLC) characterized by histology and EGFR status

33. 1350P Characteristics, treatment patterns and outcome of non-small cell lung cancer (NSCLC) patients presenting with brain-only metastatic disease

34. Osimertinib versus platinum–pemetrexed for patients with EGFR T790M advanced NSCLC and progression on a prior EGFR-tyrosine kinase inhibitor: AURA3 overall survival analysis

35. 356MO Osimertinib adjuvant therapy in patients (pts) with resected EGFR-mutated (EGFRm) NSCLC (ADAURA): Central nervous system (CNS) disease recurrence

36. LBA1 Osimertinib adjuvant therapy in patients (pts) with resected EGFR mutated (EGFRm) NSCLC (ADAURA): Central nervous system (CNS) disease recurrence

37. Overall survival (OS) from the AURA3 phase III study: Osimertinib vs platinum-pemetrexed (plt-pem) in patients (pts) with EGFR T790M advanced non-small cell lung cancer (NSCLC) and progression on a prior EGFR-tyrosine kinase inhibitor (TKI)

39. Effect of post-study immunotherapy (IO) on overall survival (OS) outcome in patients with metastatic (m) NSCLC treated with first-line durvalumab (D) vs chemotherapy (CT) in the phase III MYSTIC study

41. CNS response to osimertinib in patients with T790M-positive advanced NSCLC: pooled data from two phase II trials

42. Costs of dacomitinib versus placebo in pretreated unselected patients (pts) with advanced NSCLC: CCTG BR.26

44. Subgroup analysis of adenocarcinoma patients refractory to first-line chemotherapy from REVEL: A randomized phase III study of docetaxel with ramucirumab or placebo for second-line treatment of stage IV non–small cell lung cancer (NSCLC)

45. PD-L1 protein expression assessed by immunohistochemistry is neither prognostic nor predictive of benefit from adjuvant chemotherapy in resected non-small cell lung cancer

46. 3096 First-line monotherapy with nivolumab (NIVO) in advanced non-small cell lung cancer (NSCLC): Safety, efficacy, and biomarker analyses

47. 3113 AZD9291 in pre-treated patients with T790M positive advanced non-small cell lung cancer (NSCLC): Pooled analysis from two Phase II studies

48. 3083 AZD9291 activity in patients with EGFR-mutant advanced non-small cell lung cancer (NSCLC) and brain metastases: Data from Phase II studies

50. Tecemotide in unresectable stage III non-small-cell lung cancer in the phase III START study: updated overall survival and biomarker analyses

Catalog

Books, media, physical & digital resources